Table 3.
Representative clinical trials of delivery platforms with mRNA-LNPs against infectious diseases.
| Name of vaccine / Company | Disease | Delivery platform | Encoding sequence | NCT number (ClinicalTrials.gov.identifier) / Phase | |
|---|---|---|---|---|---|
| CV7201 / CureVAC AG | Rabies | RNAactive® | RABV-G | NCT02241135 / 1 | |
| CV7202 / CureVAC AG | mRNA-LNP | Glycoprotein G | NCT03713086 / 1 | ||
| mRNA-1440 / Moderna | Influenza | H10N8 | mRNA-LNP | Haemagglutinin | NCT03076385 / 1 |
| mRNA-1851 / Moderna | H7N9 | NCT03345043 / 1 | |||
| mRNA-1893 / Moderna | Zika virus | mRNA-LNP | prM-E protein | NCT04064905 / 1 | |
| mRNA-1443 / Moderna | Cytomegalovirus | mRNA-LNP | pp65 T cell | NCT03382405 / 1 | |
| mRNA-1647 / Moderna | Pentamer complex and full-length membrane-attached glycoprotein B |
NCT03382405 / 1 NCT04232280 / 2 |
|||
| mRNA-1273 / Moderna | SARS-CoV-2 | mRNA-LNP | Full-length spike with Proline mutations (K986P, V987P, “2P”) |
NCT04470427 / 3 (EMA) NCT05230953 / 3 |
|
| BNT 162b2 / Pfizer-BioNTech |
NCT04368728 / 3 (EMA) NCT05231005 / 3 |
||||
| CvnCoV / CureVAC AG | NCT04652102 / 2/3 | ||||
EUA: Emergency Use Authorization; K: Lysine; P: Proline; prM-E: Pre-membrane and envelope; RABV-G: Rabies virus glycoprotein; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.